by 
Anti-Neprilysin drugs are used for the treatment of chronic heart failure. Neprilysin is a zinc metallopeptidase enzyme that breaks down vasoactive peptides like BNP and ANP. Inhibition of neprilysin helps to increase the levels of these peptides that act to relieve symptoms of heart failure by enhancing renal blood flow and sodium excretion. The anti-neprilysin drugs work by inhibiting the breakdown of these beneficial peptides, thereby aiding cardiovascular function. Conditions like hypertension and diabetes are key risk factors for chronic heart failure and their rising incidence worldwide is increasing the patient pool requiring anti-neprilysin therapies. Furthermore, technological advancements in drug delivery mechanisms have improved compliance and user-friendliness of these treatments. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the anti-neprilysin market is the development of fixed dose combinations that enable once daily administration of multiple drugs. Entresto, a fixed dose combination of valsartan and sacubitril, was the first such drug approved for once daily dosing in heart failure patients. Its convenience and compliance benefits have led to high demand and sales growth. Another key ongoing trend is trials evaluating anti-neprilysin drugs for new indications beyond heart failure. For instance, BIOPROJET is conducting Phase 2 studies of its NEP inhibitor BPC162 for treatment of acute decompensated heart failure. Expanding the approved therapeutic areas would significantly expand the market potential of anti-neprilysin drugs. Partnerships between drug makers and technology companies is also a notable trend, with the objective of developing innovative delivery systems like transdermal patches for anti-neprilysin medications. This would help address the existing challenges of oral administration and enhance patient comfort.
Porter’s Analysis
Threat of new entrants: High capital requirements and stringent regulations make entry difficult for new players in the anti-neprilysin market.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over smaller players in the anti-neprilysin market.
Bargaining power of suppliers: A few major players control supply of key ingredients, giving them significant bargaining power over manufacturers.
Threat of new substitutes: Research focus on new mechanisms of action could offer alternatives to neprilysin inhibition in the future.
Competitive rivalry: Large players focus on innovation and licensing deals to strengthen their product pipelines and market position.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2024 is projected to reach US$ 1,263.3 Mn, indicating significant gains.
Regional analysis: North America currently dominates the anti-neprilysin market and is expected to continue its dominance over the forecast period. This can be attributed to early approval and adoption of neprilysin inhibitors in the region. However, Asia Pacific is anticipated to witness the fastest growth rate owing to rising healthcare spending and expanding patient pool.
Key players: Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. Major players are focusing on developing novel neprilysin inhibitors to expand their product portfolios. Licensing collaborations are also on the rise to develop potential therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
